Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pediatric Patients
100%
Phase I Study
100%
Children's Oncology Group
100%
Group Reports
100%
Depsipeptide
100%
Refractory Solid Tumors
100%
CENH3
50%
Solid Tumors
33%
Peripheral Blood Mononuclear Cells
33%
Maximum Tolerated Dose
33%
Dose-independent
33%
Immunofluorescence Assay
16%
Dose Level
16%
Dose-limiting Toxicity
16%
Recommended Phase 2 Dose
16%
Histone Deacetylase Inhibitor (HDACi)
16%
Pharmacokinetics
16%
Pharmacokinetic Profile
16%
Acetyl
16%
Hypocalcemia
16%
Histone Acetylation
16%
Sick Sinus Syndrome
16%
Concentration-time Curve
16%
Ventricular Dysfunction
16%
Objective Tumor Response
16%
T-wave Inversion
16%
Troponin Levels
16%
Inferior Leads
16%
Histone Deacetylase Activity
16%
Well Tolerated
16%
Medicine and Dentistry
Solid Malignant Neoplasm
100%
Pediatrics Patient
100%
Oncology
100%
Depsipeptide
100%
Histone H3
50%
Pharmacokinetics
33%
Infusion
33%
Peripheral Blood Mononuclear Cell
33%
Neoplasm
16%
Histone Deacetylase
16%
Heart Ventricle Function
16%
Immunofluorescence
16%
Histone Deacetylase Inhibitor
16%
Hypocalcaemia
16%
Acetic Acid Derivative
16%
Histone Acetylation
16%
Troponin
16%
Pharmacodynamics
16%
T Wave Inversion
16%
Sick Sinus Syndrome
16%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Depsipeptide
100%
Histone H3
50%
Maximum Tolerated Dose
33%
Pharmacokinetics
33%
Neoplasm
16%
Pharmacodynamics
16%
Histone Deacetylase
16%
Acetic Acid Derivative
16%
Histone
16%
Histone Deacetylase Inhibitor
16%
Troponin
16%
Hypocalcaemia
16%